Literature DB >> 15826726

Hepatic phospholipids in alcoholic liver disease assessed by proton-decoupled 31P magnetic resonance spectroscopy.

Heinz-Peter Wilhelm Schlemmer1, Tanja Sawatzki, Steffen Sammet, Ines Dornacher, Peter Bachert, Gerhard van Kaick, Rüdiger Waldherr, Helmut Karl Seitz.   

Abstract

BACKGROUND/AIMS: Alteration of the phospholipid composition of hepatic biomembranes may be one mechanism of alcoholic liver disease (ALD). We applied proton-decoupled (31)P magnetic resonance spectroscopic imaging ({(1)H}-(31)P MRSI) to 40 patients with ALD and to 13 healthy controls to confirm that metabolic alterations in hepatic phospholipid intermediates could be detected non-invasively.
METHODS: All patients underwent liver biopsy. Specimens were scored in non-cirrhosis [fatty liver (n=3), alcoholic hepatitis (n=2), fibrosis (n=4), alcoholic hepatitis plus fibrosis (n=16)], and cirrhosis (n=15). {(1)H}-(31)P spectra were collected on a clinical 1.5-Tesla MR system and were evaluated by calculating signal intensity ratios of hepatic phosphomonoester (PME), phosphodiester (PDE), phosphoethanolamine (PE), phosphocholine (PC), glycerophosphorylethanolamine (GPE), and glycerophosphorylcholine (GPC) resonances.
RESULTS: The signal intensity ratio GPE/GPC was significantly elevated in cirrhotic (1.19+/-0.22; P=0.002) and non-cirrhotic ALD patients (1.01+/-0.13; P=0.006) compared to healthy controls (0.68+/-0.04), while PE/PC and PME/PDE were significantly elevated in cirrhotic ALD patients compared to controls (1.68+/-0.60 vs. 0.97+/-0.31; P=0.02, and 0.38+/-0.02 vs. 0.25+/-0.01; P=0.002, respectively) and non-cirrhotic patients.
CONCLUSIONS: The data support that {(1)H}-(31)P MRSI appears to distinguish cirrhotic from non-cirrhotic ALD patients and confirms changes in hepatic phospholipid metabolism observed in an animal model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15826726     DOI: 10.1016/j.jhep.2004.12.032

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  8 in total

Review 1.  Assessing tissue metabolism by phosphorous-31 magnetic resonance spectroscopy and imaging: a methodology review.

Authors:  Yuchi Liu; Yuning Gu; Xin Yu
Journal:  Quant Imaging Med Surg       Date:  2017-12

Review 2.  Alcohol effects on hepatic lipid metabolism.

Authors:  Sookyoung Jeon; Rotonya Carr
Journal:  J Lipid Res       Date:  2020-02-06       Impact factor: 5.922

3.  Phosphatidylcholine contributes to in vivo (31)P MRS signal from the human liver.

Authors:  Marek Chmelík; Ladislav Valkovič; Peter Wolf; Wolfgang Bogner; Martin Gajdošík; Emina Halilbasic; Stephan Gruber; Michael Trauner; Michael Krebs; Siegfried Trattnig; Martin Krššák
Journal:  Eur Radiol       Date:  2015-01-11       Impact factor: 5.315

4.  Parametric exploration of the liver by magnetic resonance methods.

Authors:  Paul E Sijens
Journal:  Eur Radiol       Date:  2009-06-06       Impact factor: 5.315

5.  Biochemical metabolic changes assessed by 31P magnetic resonance spectroscopy after radiation-induced hepatic injury in rabbits.

Authors:  Ri-Sheng Yu; Liang Hao; Fei Dong; Jian-Shan Mao; Jian-Zhong Sun; Ying Chen; Min Lin; Zhi-Kang Wang; Wen-Hong Ding
Journal:  World J Gastroenterol       Date:  2009-06-14       Impact factor: 5.742

6.  Clinical protocols for ³¹P MRS of the brain and their use in evaluating optic pathway gliomas in children.

Authors:  Jan Novak; Martin Wilson; Lesley Macpherson; Theodoros N Arvanitis; Nigel P Davies; Andrew C Peet
Journal:  Eur J Radiol       Date:  2013-11-25       Impact factor: 3.528

Review 7.  Pathogenesis and management of alcoholic liver cirrhosis: a review.

Authors:  Yi-Wen Huang; Sien-Sing Yang; Jia-Horng Kao
Journal:  Hepat Med       Date:  2011-12-24

8.  Fluorescence spectroscopy as an efficient tool for staging the degree of liver fibrosis: an in vivo comparison with MRI.

Authors:  Shaiju S Nazeer; Ariya Saraswathy; Sachin J Shenoy; Ramapurath S Jayasree
Journal:  Sci Rep       Date:  2018-07-20       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.